Bio-Rad Stock Plummets on Weak Q1 and Lowered Outlook

Bio-Rad Shares Decline Sharply

Bio-Rad Laboratories (NYSE:BIO) stock experienced a significant drop of 9.5% on Thursday, closing at $253.48. The decline followed the company's announcement of a lowered revenue forecast for 2026 and first-quarter financial results that fell short of analyst expectations.

Financial Performance and Revised Outlook

The life sciences company reported a first-quarter adjusted earnings per share of $1.89, below the LSEG analyst consensus of $1.98. A substantial net loss of $527.1 million was recorded, largely due to a fair-value adjustment in its Sartorius AG investment. Consequently, Bio-Rad revised its 2026 revenue outlook to a range between a 3% decline and 0.5% growth, a notable reduction from the previous forecast of 0.5% to 1.5% growth.

Impact on Stock Valuation

The negative earnings report and downgraded guidance have intensified investor concerns, contributing to a significant sell-off. Including Thursday's drop, Bio-Rad's shares have now fallen 16.7% year-to-date, reflecting weakened confidence in the company's near-term growth prospects.

Summary and Forward Look

Bio-Rad faces challenges from both its recent financial performance and a more conservative long-term outlook. Investors will be closely monitoring the company's future earnings reports and strategic initiatives aimed at navigating current market headwinds and restoring growth.

FAQ

Q: Why did Bio-Rad's stock fall?
A: The stock fell because the company lowered its 2026 revenue forecast and reported Q1 earnings that missed analyst estimates.

Q: What is Bio-Rad's new revenue forecast for 2026?
A: The company now expects 2026 revenue to range from a decline of nearly 3% to growth of 0.5%.

Source: Investing.com